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Summary 
Alzheimer's disease (AD) is characterized by an early synaptic loss, which 
strongly correlates with the severity of dementia. The pathogenesis and causes of 
characteristic AD symptoms are not fully understood. Defects in various cellular 
cascades were suggested, including the imbalance in production of reactive oxygen 
and nitrogen species. Alterations in S-nitrosylation of several proteins were 
previously demonstrated in various AD animal models and patients. In this work, 
using combined biotin-switch affinity/ nano-LC-MS/MS and bioinformatic approaches 
we profiled endogenous S-nitrosylation of brain synaptosomal proteins from wild type 
and transgenic mice overexpressing mutated human Amyloid Precursor Protein 
(hAPP). Our data suggest involvement of S-nitrosylation in the regulation of 138 
synaptic proteins, including MAGUK, CamkII or synaptotagmins. 38 proteins were 
differentially S-nitrosylated in hAPP mice only. 95 S-nitrosylated peptides were 
identified for the first time (40% of total, including 33 peptides exclusively in hAPP 
synaptosomes). We verified differential S-nitrosylation of 10 (26% of all identified) 
synaptosomal proteins from hAPP mice, by Western blotting with specific antibodies. 
Functional enrichment analysis linked S-nitrosylated proteins to various cellular 
pathways, including: glycolysis/gluconeogenesis, calcium homeostasis, ion and 
vesicle transport, suggesting a basic role of this post-translational modification in the 
regulation of synapses. The linkage of SNO-proteins to axonal guidance and other 
processes related to APP metabolism exclusively in the hAPP brain, implicates S-
nitrosylation in the pathogenesis of Alzheimer’s disease. 
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Introduction 
The role of nitric oxide (NO) as a signaling molecule in the central nervous 
system was discovered in 1988 (1). The brain and cerebellum in particular, contain 
one of the highest activities of NO-forming enzyme (NO synthase, NOS) in all tissues 
examined (2, 3). Nitric oxide is a freely diffusible, very reactive radical molecule. It 
readily reacts with various endogenous substrates forming i.e. iron and copper 
adducts in prosthetic groups of proteins (4), peroxynitrite in the reaction with reactive 
oxygen species, ROS (5) and S-nitrosothiols with endogenous low-molecular weight 
thiols like cysteine and glutathione (6). One of the aspects of NO physiology is 
formation of S-nitrosylated proteins. Cysteine residues, post-translationally modified 
by S-nitrosylation, exert control over the activity of proteins and pathways in which 
they are involved, analogous to the addition of a phosphate group during 
phosphorylation (7, 8). S-nitrosylation is a key mechanism in the transmission of NO-
based cellular signals in vital cellular processes, including: transcription regulation, 
DNA repair, autophagy and apoptosis (8).  
The role of protein S-nitrosylation underlying pathology of various diseases, 
including cancer (9, 10), heart condition (11-13) and neurodegenerative disorders 
has been extensively reviewed (8, 14). In the brain, aging processes and 
environmental factors cause protein S-nitrosylation which in turn may enhance 
misfolding of proteins, induce apoptosis or autophagy, mitochondrial fragmentation 
and affect normal synaptic functions (8). S-nitrosylation of proteins plays an important 
role in neurons. For example, N-methyl-D-aspartate receptor (NMDAR) and caspase 
enzyme activity can be decreased by S-nitrosylation, thereby facilitating 
neuroprotection (15). This finding led to development of nitro-memantine, a nitric 
oxide donor and selective NMDAR interacting drug. It selectively S-nitrosylates the 
NMDA receptor and prevents its’ hyperactivation, also observed in Alzheimer’s 
disease (16). On the contrary, S-nitrosylation of protein-disulfide isomerase (17), 
dynamin-related protein 1 (18), glyceraldehyde dehydrogenase (19), cyclo-
oxygenase-2 (20), N-ethylmaleimide sensitive protein (21), Parkin (22-24), Gospel 
(25), cyclin dependent kinase- 5 (26), mitochondrial complex I (27), stargazin (28), 
and serine racemase (29), has been related to severe neuropathological alterations 
in the brain due to induction of: protein misfolding/ aggregation, mitochondrial 
dysfunction, bioenergetic compromise, synaptic injury and subsequent neuronal loss.  
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Alzheimer’s disease is the most prevalent form of human dementia, with a 
frequency that progressively increases in aging societies (30). The temporal 
progression of AD exhibits a highly variable pattern among patients and is not fully 
understood (31). Environmental, age-related and genetic factors have been proposed 
to contribute to pathogenesis of the disease. Defects in various signaling pathways 
regulated by post translational modifications of proteins (PTM) i.e. phosphorylation, 
were suggested to be the determinant parameter for disease progression (32-35). A 
pivotal role in development and progression of late-onset AD and various other age-
dependent dementias has been attributed to inflammatory and oxidative stress 
cascades in the brain (36, 37). Reactive oxygen (ROS) and reactive nitrogen species 
(RNS) play a crucial role in these processes (38). The consequences of oxidative and 
nitrosative stress, such as lipid peroxidation, DNA oxidation and nitrosative/oxidative 
PTM of brain proteins were detected in global and targeted proteomic analyses in AD 
patients (14, 39-43). On the other hand, a multitude of evidence suggests that 
physiological levels of ROS and RNS are implicated in various cell signaling 
cascades (reviewed in (44-47)).  
Various transgenic mouse models, based on the overexpression of mutant 
form(s) of human APP and recapitulating the AD phenotype are currently used to 
investigate mechanisms underlying disease pathology (48, 49). The present study 
utilized one such model, a transgenic mice expressing human APP with London 
mutation and its wild-type, aged-matched counterparts, for targeted, differential 
proteomic analysis of S-nitrosylation of proteins located at the synaptic terminals.  
The Biotin Switch Technique (BST) and its modification, SNOSID (SNO Site 
Identification) (50); in combination with mass spectrometry have been used in 
targeted proteomics studies of cellular “S-nitrosomes”. BST relies on selective 
ascorbate reduction of S-nitrosothiols to generate free thiol groups in the presence of 
other thiol derivatives (51), whereas SNOSID (SNO Site Identification) involves 
biotinylation of protein SNO-Cys residues, trypsin digestion, affinity purification of 
biotinylated-peptides and sequencing by tandem MS (50). The majority of such 
studies were undertaken to identify targets of S-nitrosylation induced by nitric oxide 
donor treatment (52-54).  
It is however, difficult to extrapolate results of donor induced studies to an in 
vivo situation, where cysteine S-nitrosylation is dependent on the overall redox state 
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of a cell and its unknown levels of nitrosylating compounds (55). In this work, we 
optimized the BST for MS-based global analysis of endogenous protein S-
nitrosylation. Our study was designed to test the hypothesis that redox imbalance 
and changes in activity of nitric oxide synthase(s) influence the level and pattern of 
endogenous S-nitrosylation of synaptic proteins. Among 138 identified synaptosomal 
SNO-proteins, 38 were differentially S-nitrosylated in the hAPP mouse brain. Our 
data suggest a possibility of sequential S-nitrosylation, similarly as for other post-
translational modifications, i.e. phosphorylation. Focused systematic proteomics 
approaches addressing the role of cysteine post-translational modifications in the 
brain can lead to new mechanism-based therapies for various neurodegenerative 
disorders including AD. 
 
Experimental procedures 
Reagents 
Bradford reagent, sucrose, Ficoll, neocuproine and sodium ascorbate were 
from Sigma. S-Methyl methanethiosulfonate (MMTS) was from Fluka. Neutravidin-
agarose and biotin-HPDP were purchased from Thermo Scientific. Sequencing grade 
modified trypsin was obtained from Promega. Complete protease inhibitor cocktail 
was from Roche diagnostics. ECL chemiluminescence reagents were purchased 
from Amersham Biosciences. Antibodies directed against gamma enolase (Eno2) 
and glial fibrillary acidic protein (Gfap) were obtained from DAKO. Anti-adaptor 
protein complex AP-2 (Ap2a1), anti-peroxiredoxin 3 (Prdx3), anti-peroxiredoxin 6 
(Prdx6) and streptavidin HRP-conjugated secondary antibodies were purchased from 
Abcam. Primary antibodies, directed against neural cell adhesion molecule 1 
(Ncam1), synaptotagmins-1/2 (Syt1/Syt2), neurocalcin delta (Ncald), glyceraldehyde-
3-phosphate dehydrogenase (Gapdh), ras-related C3 botulinum toxin substrate 1 
(Rac1), inducible nitric oxide synthase 2 (Nos2; iNos) and neuronal nitric oxide 
synthase 1 (Nos1; nNos), as well as secondary antibodies: rabbit anti-mouse IgG, 
rabbit anti-goat IgG and goat anti-rabbit IgG antibody were purchased from Santa 
Cruz Biotechnology. PVDF (0.22 µm) membrane was from Millipore. 
Transgenic mice 
Transgenic AD mice used in this study were generated in Prof. Fred van 
Leuven’s laboratory (K.U. Leuven) as described by Moechars et al. (56), and kept at 
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the Animal House of Polish Academy of Sciences Medical Research Center. The 
transgenic mice express human Amyloid Precursor Protein with London mutation 
[Tg(APPV717I)], under the control of the mouse Thy1-gene promoter (called later as 
hAPP mice). 14-15 month female heterozygous mice were included in the study. 
Control aged-matched mice (FVB/N, called later as FVB mice) were of the same 
genetic background. All experiments were performed in accordance with Polish 
guidelines for care and use of laboratory animals. 
Synaptosome isolation 
Synaptosomes were prepared from brains of 14-15 months old, female FVB 
and hAPP mice, as described (57, 58). Four mice of the same age were decapitated 
and their brains immediately removed and homogenized using Dounce homogenizer, 
in 6 ml of buffer A containing 5mM Hepes pH 7.4, 0.32 M sucrose, 0.2 mM EDTA, 20 
mM MMTS (a free thiol blocking reagent) and protease inhibitor cocktail. The 
homogenate was centrifuged (2.500 x g for 5 minutes) to yield pellet and supernatant 
fractions. Supernatant was subsequently centrifuged at 12.000 x g for 5 min. The 
obtained pellet was resuspended in buffer A, placed onto a discontinuous Ficoll 
gradient and centrifuged at 70.000 x g for 45 minutes. Synaptosomal fraction was 
collected, resuspended in buffer A and centrifuged at 20.000 x g for 20 min. Purified 
fraction of synaptosomes was used in all proteomic experiments. 
Biotin Switch Technique 
Substitution of S-nitrosylated Cys (SNO-Cys) sites with S-biotinylated Cys in 
synaptosomal protein lysates was based on a previously described BST procedure 
(51). In our study we optimized concentration of used reagents and the time reactions 
to increase the specificity and sensitivity of the method. Mouse synaptosomal 
fractions were dissolved in HEN buffer containing 250 mM Hepes pH 7.7, 1 mM 
EDTA and 0.1 mM neocuproine. To avoid rearrangements of  thiol modifying groups, 
the protein mixture was treated with 2 volumes of a thiol blocking solution containing 
250 mM Hepes pH 7.7, 1 mM EDTA and 0.1 mM neocuproine (copper ion chelator), 
5% SDS, 20 mM MMTS at 50 ºC for 20 minutes with agitation (in the dark). To 
remove excess of reagents, proteins were precipitated with acetone and 
resuspended in the same volume of HEN buffer containing 2.5 % SDS. The obtained 
protein solutions were divided into two equal parts. One part was treated with a 
mixture of 400 µM Biotin-HPDP and 5 mM sodium ascorbate. The second half was 
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used as a negative control for experiments and treated with 400 µM biotin HPDP 
without sodium ascorbate. All samples were incubated in the dark for 1.5 hours at 
room temperature (RT). The proteins were again acetone-precipitated, resuspended 
in the same volume of HEN buffer containing 2.5 % SDS and diluted with two 
volumes of neutralization buffer (20 mM Hepes, pH 7.7, 100 mM NaCl, 1 mM EDTA). 
100 μl of neutravidin-agarose beads was added to the solution and incubated for 1 hr 
at room temperature with agitation. Afterwards, the beads were washed five times 
with 20 mM Hepes, pH 7.7, 600 mM NaCl, 1 mM EDTA and incubated with elution 
buffer containing 50 mM Tris, pH 8.0, 1 mM EDTA, and 50 mM DTT, for 20 minutes 
at RT with gentle agitation. The supernatants containing enriched SNO-proteins were 
used in subsequent Western blot analyses for validation of detected SNO-sites.  
Western blot detection of nNos and iNos in FVB and hAPP mouse brains  
Brain homogenates were analyzed for nNos and iNos protein expression using 
Western blot method. 20 µg of protein extracts from whole brains of FVB and hAPP 
mice, respectively, were separated by reducing 10% SDS–PAGE. Separated proteins 
were transferred onto PVDF membrane. The membranes were first blocked with 
caseine-based buffer (Sigma) and incubated with primary antibodies to nNos and 
iNos. Membranes were then probed with secondary antibodies raised against the 
appropriate species. Equal protein loads were assessed with antibodies against 
Gapdh and by Ponceau S staining on the blots. Western blots were developed using 
ECL chemiluminescence. The scanned blots were quantified densitometrically using 
GelQuant software and relative protein abundance of nNos and iNos normalized to 
the expression of Gapdh. Heteroschedastic two-tailed t-test was used to assess the 
changes in expression. 
Western Blot analysis of protein S-nitrosylation pattern in FVB and hAPP 
synaptosomes 
Total synaptosomal protein fractions after BST procedure but without 
neutravidin-based affinity purification were resolved using reducing 10% SDS-PAGE. 
Selectively biotinylated proteins were captured using streptavidin-HRP conjugated 
antibodies and visualized by ECL chemiluminescence.  
 Western blot detection of differential S-nitrosylation in the brain 
All fractions (including total synaptosomal fractions and those from different 
steps of BST procedure) were separated using 12% SDS-PAGE and transferred to 
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PVDF membrane (0.22 μm). The membranes were first blocked with caseine-based 
buffer (Sigma) and incubated with primary antibodies followed by secondary HRP-
conjugated antibodies. Protein bands were detected using the ECL 
chemiluminescence system (Amersham Biosciences). The fractions containing 
enriched S-nitrosylated proteins, from FVB and hAPP synaptosomes were quantified 
densitometrically with GelQuant software. Heteroschedastic two-tailed t-test was 
used to statistically assess the changes in endogenous protein S-nitrosylation. 
SNOSID 
The synaptosomal protein fractions containing biotin labeled proteins (biotin 
labeling step described in the BST section) were digested using sequencing grade 
modified trypsin for 16 hours at 37 ºC. Digestion was terminated using protease 
inhibitors cocktail. Tryptic peptides were incubated with 100 μl of neutravidin beads 
for 1 hour at RT. Beads were then washed 5 times with 1 ml of wash buffer. Peptides 
bound to neutravidin resin were eluted with 150 μl of elution buffer containing 30 mM 
dithiotreitol. Eluted, cysteine-containing peptides were alkylated using 200 mM 
iodoacetamide. In the next step, peptides containing fractions were concentrated 
using SpeedVac and diluted with 1% trifluoroacetic acid/water (v/v) to a final 
concentration of 0.1 % TFA.  
LC-MS and LC-MS/MS analysis 
Each enriched SNO-peptides containing sample was measured twice: once 
with LC-MS/MS (tandem mass spectrometry), to identify the enriched SNO tryptic 
peptides, and once in LC-MS mode (resulting in profile spectrum), to attain label-free 
quantitative data based solely on peak intensities. All MS runs were separated by 
blank ones to reduce carry-over of peptides from previous samples. The 
measurements were carried in Nano Aquity Liquid Chromatography system (Waters) 
coupled to LTQ-FTICR mass spectrometer (Thermo Scientific). SNO-peptides in 
0.1% TFA were loaded from a cooled (10 ºC) autosampler tray to a pre-column 
(Symmetry C18, 180 µm × 20 mm, 5 µm Waters) and resolved on BEH130 column 
(C18, 75 µm x 250 mm, 1.7 µm, Waters), in a gradient of 5-30% acetonitrile / 0.1% 
formic acid for 70 minutes at a 0.3 µl/min flow rate. The UPLC system was directly 
connected to the ion source of the mass spectrometer. The resolution of mass 
spectrometer was set to 50.000 for MS acquisitions with m/z measurement range of 
300-2000 Th. The quantitative LC-MS runs were converted into 2D heat-maps (with 
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retention time and m/z as vertical and horizontal axes, respectively) using in-house 
designed finnigan2Pipe data conversion tool (59, 60). The format of resulting data 
met the requirements of NMRPipe software (http://spin.niddk.nih.gov/NMRPipe).  
For LC-MS/MS runs, we utilized the data dependent acquisition (DDA) mode, 
selecting the 5 most intense signals in each MS spectrum for fragmentation. Dynamic 
exclusion was activated, with m/z tolerance of 0.05-1.55 and duration of 15. Up to 5 
fragmentation events were allowed for each parent ion. The peak-picking was 
performed using MascotDistiller software (version 2.3, MatrixScience). Mascot search 
engine was used to survey data against UniProtKB/Swiss-Prot database version 
2013_10 (45889 sequences). Mascot search parameters were set as follows: 
taxonomy Mus musculus, fixed modification - cysteine carbamidomethylation, 
variable modification - methionine oxidation, parent ion mass tolerance - 40 ppm, 
fragment ion mass tolerance - 0.8 Da, number of missed cleavages - 1, enzyme 
specificity - semi-trypsin. The false-positive rate (FDR) values for Mascot 
identifications were calculated using the concatenated target/decoy database search 
strategy (merged target/decoy databases generated with in-house developed 
software (http://proteom.ibb.waw.pl/decoy/index.html). This analysis demonstrated 
that for peptides with Mascot score > 30, the FDR did not exceed 0.29%. 
 Using in-house developed software Mscan (http://proteom.ibb.waw.pl/mscan), 
the peptides identified in all LC-MS/MS runs (both from FVB and hAPP samples) 
were merged into one selected peptide list (SPL). Each peptide in the SPL was 
characterized by its amino acid sequence, LC retention time, m/z value and charge 
state values of corresponding ions. The SPL was then used to localize the peptide 
ions on 2D heat-maps generated from LC-MS runs (Supplemental Figure 1), and to 
obtain the quantitative values (LC peak intensities). Peptide ion localization was 
performed with in-house developed TagProfile software (60). Further manual data 
inspection (mainly to account for retention time variation in different LC runs and deal 
with faulty assignment cases) and quantitative analysis was achieved using in-house 
developed software Msparky (http://proteom.ibb.waw.pl/msparky), a modified version 
of Sparky NMR software (http://www.cgl.ucsf.edu/home/sparky) (59-63). Acceptance 
criteria for manual data inspection included: m/z value deviation - 20 ppm, retention 
time deviation - 10 minutes, envelope root mean squared error (a deviation between 
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the expected isotopic envelope of the peak heights and their experimental values) - 
0.7. Charge state value was also inspected. 
The SPL with obtained quantitative values was then reduced so that each 
cysteine was represented by single peptide entry with one quantitative value. In the 
final step, two lists of SNO-peptides/proteins from 14 month old mice were 
generated, one for hAPP and one for FVB. By comparing these lists, three sets of 
SNO-Cysteine peptides were determined: 1) identified only in FVB (corresponding 
proteins named as S-nitroso-wt), 2) identified in both FVB and hAPP (corresponding 
proteins named as S-nitroso-all), and 3) observed exclusively in hAPP synaptosomes 
(corresponding proteins named as S-nitroso-diff). These sets are presented in 
Supplemental Table S1. The annotated spectra displaying sequence information of 
all identified SNO-peptides are presented in Supplemental Figure S2. All raw data 
from LC-MS and LC-MS/MS measurements are available at the public repository 
ProteomicsDB (project entitled: “synaptosomes”; 
https://www.proteomicsdb.org/proteomicsdb/#projects/4161?accessCode=f5247f4f64
cc04f627a141ffa16b4d7d836dfabaf4c33729a990b1794723ea1b). 
To compare the number of identified SNO-proteins and SNO-sites in all three 
sets we utilized Venny (http://bioinfogp.cnb.csic.es/tools/venny/) (64). Positions of 
SNO-Cys sites, the number of cysteines in protein sequence, and previously 
identified entries with literature references are listed in the same supplemental table. 
Comparison of mouse and human differential SNO-peptide sequences was achieved 
with Uniprot/blast program (http://www.uniprot.org/blast/). 
Functional analysis of proteomic data 
In order to connect the human orthologs of mouse differentially S-nitrosylated 
gene products with Amyloid Precursor Protein (APP) we utilized GeneMania 
(www.GeneMania.org; which indexes 1,464 association networks containing 
292,680,904 interactions mapped to 149,747 genes from 7 organisms, last update 
06/2013) (65, 66). Human orthologs of mouse genes were assigned with NCBI 
homologene (http://www.ncbi.nlm.nih.gov/sites/homologene/). NCBI Gene unique 
identifiers of human orthologs of mouse genes representing differentially mouse 
SNO-proteins identified in FVB or hAPP mice were used as an input for functional 
network analyses. The networks were calculated and drawn using GeneMania 
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reference real- and binary-valued interaction networks consisting of physical, genetic, 
predicted and pathway interaction datasets. For weighting of the networks we used 
Gene Ontology biological process (GO BP) algorithm from GeneMania, which 
assigns weights in order to maximize connectivity between all input genes in a given 
ontology class.  The number of measured SNO-sites was included as one of the 
parameters in network depiction. In cases when the number of SNO-sites in a 
peptide after neutravidin affinity could not be unambiguously assigned, for simplicity, 
we chose the highest possible number of SNO-sites, according to a number of 
available Cys in a given sequence. 
SNO-datasets were functionally analyzed using ClueGOv1.4, a Cytoscape 
plug-in (http://www.ici.upmc.fr/cluego/) (67), which applies GO/KEGG hierarchical 
characteristics for clustering of term distributions. As a reference set for term 
enrichment  calculations we utilized genes (NCBI unique Gene identifiers), 
corresponding to human orthologs of MS- measured mouse synaptosomal proteins 
(Malinowska et al., submitted), enriched with non-redundant genes from 2 most 
comprehensive, expert- curated synaptic databases (SynsysNet; 
http://bioinformatics.charite.de/synsys/  (68) and SynaptomeDB; 
http://psychiatry.igm.jhmi.edu/SynaptomeDB/ (69)). Thus constructed “synaptic 
reference set” comprises of more than 5600 NCBI unique human genes. The 
enrichment of GO biological process functional categories in this reference set is 
presented in Supplemental Figure S3. A Venn diagram demonstrating the 
distribution of genes among three database sources in “synaptic reference set” is 
presented in Supplemental Figure S4. P values for term enrichment were calculated 
using right-sided hypergeometric test. The nodes in functionally grouped networks 
were linked based on their kappa score level (≥0.3) in ClueGO.  
13 
 
Results 
 
The protein expression of nitric oxide synthases is elevated in hAPP mouse 
brain 
Expression levels of nNOS and iNOS in total brain cortex lysates from 14 
months old FVB and hAPP mice were compared by Western blot analysis. A 
significant increase in the protein expression levels of iNOS (fold change= 4.94, n=4, 
P=4.74E-06), and nNOS (fold change= 2.05, n=2) was observed in hAPP mouse 
brain in comparison to FVB mouse brain, consistent with previous observations (70, 
71). Bands of 130 and 160 kDa corresponded to iNOS and nNOS, respectively 
(Figure 1). 
Endogenous protein S-nitrosylation is increased in hAPP synaptosomes  
To assess whether the increased expression of nitric oxide synthases visible 
in the hAPP mouse brain results in pattern changes of endogenous protein S-
nitrosylation, we used a BST assay in which SNO-proteins are selectively labeled by 
biotin, followed by Western blot detection with anti-biotin antibodies. Numerous 
protein bands across a broad mass range were revealed, both in FVB and hAPP 
derived synaptosomal fractions indicating the presence of endogenously S-
nitrosylated proteins (Figure 2, lane 3 and 4). The number and intensities of specific 
bands were significantly increased in hAPP synaptosomes. No bands were detected 
in negative control experiments confirming selectivity of the ascorbate reduction of 
SNO-bonds. 
Endogenously S-nitrosylated proteins in FVB and hAPP synaptosomes were 
identified using SNOSID-LC-MS/MS assay  
BST and anti-biotin Western blot analysis suggested that synaptosomal 
proteins of a wide molecular mass range are affected by S-nitrosylation.  
In our work, we utilized SNOSID technique developed by Hao et al. (50) for 
non- targeted proteomic identification of specific cysteine residues in proteins which 
are modified by posttranslational S-nitrosylation. The method is based on exclusive 
affinity capture of formerly nitrosylated, cysteine containing tryptic peptides, which are 
labeled with biotin similarly as in the initial steps of BST assay. The overall scheme of 
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S-nitrosylation enrichment methodology used in this work is presented in the Figure 
3.  
We explored SNOSID peptide enrichment technique combined with LC-
MS/MS peptide identification to precisely ascertain the targets of S-nitrosylation 
among synaptosomal proteins. Among 138 identified SNO-proteins, 38 were present 
only in hAPP mice synaptosomes (Figure 4A, Table 1 and Supplemental Table 
S2). A total of 249 SNO-sites were identified, including 108 sites found exclusively in 
hAPP brain (Figure 4B). Sequence alignment of mouse differentially S-nitrosylated 
peptide sequences with their human counterparts demonstrated that almost all SNO- 
Cys are conserved between both species (Supplemental Table S3). 95 SNO- 
peptides were identified for the first time (40% of total, 33 of which were solely 
present in hAPP synaptosomes). 49 of the hAPP differential SNO-sites were 
detected in proteins S-nitrosylated in FVB mice but at a different Cys residue, i.e. in 
calcium/calmodulin-dependent protein kinase II (CamkII), succinate-CoA ligase 
(Suclg1) or neurofascin (Nfasc). Interestingly, for aconitate hydratase (Aco2) we 
detected an exchange of a single SNO-site from Cys385 to Cys592. The number of 
differential SNO-peptides, i.e. SNO-sites in FVB and hAPP mice differs from that of 
differential proteins, which suggests that some proteins are possibly sequentially S-
nitrosylated.  
The overall pattern of S-nitrosylations in FVB and hAPP synaptosomes is 
depicted in Supplemental Figure S5. Figure 4C schematically portrays the 
possibilities for SNO-based regulation of synaptosomal proteins as a result of the 
hAPP overexpression in mice.  
Synaptosomal S-nitrosylated proteins in FVB mouse brain represent a variety 
of protein classes 
In order to decipher molecular mechanisms in the synapse, in which S-
nitrosylation of proteins might play a distinct role, we performed functional enrichment 
analyses of terms from Gene Ontology Biological Process (GOBP) and KEGG. For 
this purpose we utilized a comprehensive “synaptic reference set”, comprising over 
5,600 genes (see description in Material and Methods) and ClueGO algorithm. Two 
sets of identified human orthologs of mouse S-nitrosylated synaptosomal proteins 
(S-nitroso-wt and S-nitroso-diff sets) were analyzed. The analyses of S-nitroso-wt set 
(Figure 5 and Supplemental Tables S4) revealed multiple enriched functional 
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categories. Terms related to: generation of precursor metabolites (P=3.11E-15), 
gluconeogenesis (P=7.41E-08), synaptic transmission (P=1.22E-4) and 
neurotransmitter transport (P=1.07E-03) were significantly statistically enriched in 
GO BP analyses of S-nitroso-wt set (Figure 5 and Supplemental Table S4A). In-
depth analysis of KEGG pathways pinned down additional enriched terms related to 
other metabolic processes, i.e. TCA cycle, oxidative phosphorylation and synaptic 
organization, to name but only a few of those most associated with the normal 
physiology of neurons.  
The multiplicity of enriched terms suggests that S-nitrosylation is a global post-
translational modification, with a role in modulating the function of different classes of 
proteins within the synapse microenvironment. Interestingly, 16 SNO-proteins from 
FVB mice (~12% of all identified mouse brain synaptosomal SNO-proteins; 
Supplemental Table S4B) formed a cluster of functionally grouped terms (Figure 5) 
previously implicated in Alzheimer’s, Parkinson’s and Huntington’s diseases.  
Differentially S-nitrosylated proteins in hAPP mouse brain are linked to axon 
guidance and vesicle trafficking and form a highly- connected network  
Analysis of S-nitroso-diff proteins with ClueGO and GO BP revealed two major 
functional clusters. Similarly as in the wild-type mouse brain, a six node sub-network 
related to gluconeogenesis/glycolysis and generation of precursor metabolites and 
energy was revealed (comprising 9 out of 38 analyzed proteins, Supplemental Table 
S5A). The second sub-network contained 11 nodes including axon guidance 
(GO:0007411), which presented the most enriched group term (P=4.76E-03; Figure 
6A-B). Other nodes which belong to this functional cluster included i.e. vesicle 
mediated transport and exocytosis, both of which are linked to APP neuronal 
trafficking (Figure 6B and Supplemental Table S5B) (72, 73). Parallel functional 
analyses using KEGG pathways supported the finding that proteins in the S-nitroso-
diff set are linked to axon guidance and regulation of actin cytoskeleton (P=3.71E-02, 
Figure 6B and Supplemental Table S5B).  
In this study, human APP protein expression in mouse brain was the 
distinguishing parameter used to model some aspects of Alzheimer disease. 
Therefore, we aimed to assess the connectivity of the identified differentially S-
nitrosylated synaptosomal proteins to APP. We searched for human orthologs of 
mouse SNO-proteins (Supplemental Table S1) and connected them using 
16 
 
GeneMania. We connected 36 (out of 38) differentially S-nitrosylated orthologs with 
APP using multiple interaction data (Figure 6C and Supplemental Tables S6A-D). 
59 nodes in the calculated network (Supplemental Table S6A) were connected by 
genetic (57 links) and physical interactions (34 links), as well as pathway sharing (27 
links). 34 interactions in the network were derived from predicted, mostly interologous 
interactions (Supplemental Table S6B). Five SNO-proteins were directly connected 
to APP either via physical interactions (Gapdh/GAPDH), genetic interactions 
(Ube2d3/UBE2D3, Negr1/NEGR1), and pathway sharing (Gapdh/GAPDH and 
Negr1/NEGR1) or predicted to interact from homologous interactions 
(Ncam1/NCAM1). Actb/ACTB (β-actin) has been detected as part of the same 
molecular complex with APP (74). The most enriched functional category of the 
network, participation in cytoplasmic vesicle (P=2.74E-04) was shared by 9 proteins, 
including APP and 6 SNO-proteins, namely AP2A1, ALDOA, HSPA8, NCALD and 
SYT1, SYT2. Subsequent analysis of the axon guidance sub-network (P=1.73E-03) 
revealed that it contained 10 proteins, including APP, PRNP, LIMK1 and AGRN and 
6 human orthologs of differentially nitrosylated proteins (from S-nitroso-diff set): 
ACTB, AP2A1, CFL1, KRAS, NCAM1 and RAC1 (Figure 6C and Supplemental 
Table S6C).  
Validation of differential protein S-nitrosylation detected using Biotin Switch-
LC-MS/MS by Western blotting  
Western blot analysis was used to validate the results of MS based 
identifications of selected, differential SNO-proteins implicated in AD (75-79). 
Immunoreactivity was traced in different fractions during BST enrichment of 
S-nitrosylated synaptosomal proteins from FVB and hAPP mice. Ten differentially S-
nitrosylated proteins from different functional classes were chosen for MS data 
validation (including a novel one described in this study, neurocalcin delta, Ncald). 
Figure 7 demonstrates the results of immunoblotting with specific antibodies 
recognizing mouse Ncam1, Ap2a1, Gfap, Eno2, Syt1/Syt2, Gapdh, Ncald, Prdx3 and 
Rac1, respectively. The total expression of studied proteins was unchanged in the 
hAPP and FVB brains (lanes 1 and 2), which is consistent with the results of 
differential proteomics expression analysis in these mice (Malinowska et al., 
submitted). Following BST enrichment, positive signals were observed only in 
fractions derived from hAPP brain synaptosomes (lane 7), but not in the FVB brain 
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(lane 5), confirming the MS-based identification of differentially SNO-proteins. An 
internal control in which S-nitrosylation does not change between FVB and hAPP 
(includes 2 synaptosomal proteins, synaptophysin, Syp, and peroxiredoxin, Prdx6; 
compare lanes 5 and 7, Figure 7A-B) was included. 
Interestingly, a specific monoclonal antibody against enolase 2, Eno2 was 
used to positively identify S-nitrosylation of this protein in the hAPP brain. In MS 
based analyses we could not distinguish whether this protein is differentially S-
nitrosylated in hAPP mice or an additional site is modified by S-nitrosylation upon 
APP overexpression (Supplemental Table S2A). The identified SNO-peptide in the 
FVB synaptosomes was also shared between three enolases, Eno1, Eno2 and Eno3, 
precluding a proper assignment. The results of Western blot analysis indicate that 
there is no S-nitrosylation of Eno2 in the wild-type mouse brain. Overall, we have 
validated the differential SNO of 10 proteins in hAPP synaptosomes.  
 
Discussion 
Signaling by RNS is mainly carried out by targeted modifications of critical 
cysteine residues in proteins, including S-nitrosylation, S-oxidation, and lipid nitration 
(80). Despite thousands of SNO-proteins currently identified (~3000), the observed 
specificity of S-nitrosylation in terms of target proteins and specific Cys residues is 
not entirely understood (81, 82). S-nitrosylated proteins are implicated in the 
pathogenesis of various neurodegenerative diseases, including Alzheimer’s, 
Parkinson’s and Huntington’s diseases, amyotrophic lateral sclerosis, Friedreich 
ataxia and many others, where they influence the onset or development of 
neurodegeneration (8, 23, 83-85).  
One of the key pathological features of patients with neurodegenerative 
disorders including AD is impaired signaling at the synapse. Our proteomics study 
was designed to search for and identify endogenous regulation of synaptic proteins 
by S-nitrosylation. We also probed for a direct association of protein S-nitrosylation 
with an important aspect of AD development, namely overexpression of A.  
Synaptosomes are a well-recognized model for studies of synaptic complexity 
in the brain (86, 87). They contain complete presynaptic terminals, with postsynaptic 
membranes and densities, as well as other components necessary to store, release, 
and retain neurotransmitters. Viable mitochondria for production of ATP and active 
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energy metabolism, are also present in synaptosomes (88). Moreover, it has recently 
been proposed that S-nitrosylation is effectively dependent on the subcellular 
localization of proteins, with short-range linkage to synaptic transmission in neurons 
(89). Therefore, in order to reduce the complexity of the analyzed system we decided 
to narrow our studies to proteins involved in synaptic functions, employing fresh 
synaptosomal preparations routinely used for proteomic screening of affected 
pathways in the brain (90, 91).  
A combination of different approaches based on BST and immunoprecipitation 
with S-nitrosothiol antibodies, followed by 2D-electrophoresis and LC-MS/MS was 
recently introduced by Zahid et al. (92), to study differentially S-nitrosylated proteins 
in the human AD brain. However, in their study, total brain lysates from cortex, 
hippocampus and substantia nigra (post-mortem frozen brain tissue) were utilized, 
and only 45 SNO-proteins identified (without recognizing sites of modification), 
impeding detailed analysis of the affected pathways in the synapse. 
Human brain tissue samples are difficult targets for differential proteomics. 
Samples are obtained post mortem with usually longer interval times in comparison 
to the life-span of most SNO-proteins. Special autopsy programs for AD patients, 
aimed at analysis of labile PTM within 4-h post mortem interval are still rare (i.e. 
Rapid Autopsy Program of the University of Kentucky Alzheimer’s Diseases 
Research Center, UKADRC (93)). Moreover, freezing and thawing of tissues leads to 
artifacts in tyrosine nitration and cysteine nitrosylation if homogenization is not 
performed in the presence of thiol blocking agents (94). As such, instead of analyzing 
highly variable human tissue samples (vide i.e. SNO Drp1 level analysis in AD 
patients (95)) we opted for a well-defined tg AD mouse model for differential analysis 
of synaptic SNO-proteins. Moreover, the inclusion criteria used for selection of 
differential protein sets proposed in our work were very stringent. A protein has been 
defined as differentially S-nitrosylated only if it was repeatedly observed in hAPP 
brain synaptosomes, and not detected in the age-matched wild-type controls. In the 
authors opinion this led to highly selective identification of differentially SNO synaptic 
proteins in the hAPP brain.  
Despite its utility in identifying SNO-Cys modiﬁcation in proteins, the BST and 
SNOSID methods are constrained by several limitations. Each step of these 
techniques is a potential source of methodological errors. One of such limitations is 
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linearity (with respect to protein input and biotinylation). The blocking step of the BST 
shall also be taken into consideration, as some protein thiols can be resistant to 
complete blocking, resulting in high levels of SNO-independent biotinylation. Another 
question which was raised by some authors is the specificity of the method. The 
other constraint is a usage of ascorbate, which was suggested to have a potential to 
reduce the disulfide bonds. This has been later challenged by observations that thiol-
dependent reduction of dehydroascorbate to ascorbate, a scenario supported by 
extensive in vitro and in vivo experimentation is thermodynamically favored. Another 
limitation of BST method is related to the presence of metal ions, which can 
compromise the BST specificity, including production of ascorbate and hydroxyl 
radicals. Following a number of publications which discussed limitations of 
BST/SNOSID enrichment methods (96-99), in this work we developed special sample 
procedures to detect and identify S-nitrosylated proteins in the synapse. We utilized 
SNOSID enrichment of previously S-nitrosylated tryptic peptides to pinpoint not only 
the S-nitrosylated proteins but also precise sites of SNO modification. Furthermore, 
the aim of our study was not to identify the largest number of proteins susceptible to 
S-nitrosylation in the synapse milieu but rather to prove that the NO-based regulation 
is not random i.e. related only to higher amount of produced RNS. We also aspired to 
demonstrate that this process is highly confined to specific key molecules and/or 
pathways, and is modified upon AD symptoms progression in mice.  
By combining an optimized SNOSID method coupled with LC-MS/MS, we 
identified 138 S-nitrosylated proteins with 249 SNO-sites (Figure 4) and 
corresponding changes in pattern of their S-nitrosylation. With this approach 95 SNO-
peptides were identified for the first time, while 76% of all identified SNO-proteins 
were previously described to be endo/exogenously S-nitrosylated in the literature 
(Supplemental Table S2, see literature references). We also observed that almost 
all SNO-Cys sites in the SNO-diff set (Supplemental Table S3) were conserved 
between human and mouse, suggestive for importance of these sites in the PTM 
regulation of synaptic functions in the AD brain. An overlap of 25 S-nitrosylated-
proteins (Table 1 and Supplemental Table S2) was observed between this study 
and the one by Zahid et al. (92).  
To establish the functional connection between identified S-nitrosylated 
synaptosomal proteins, we applied stringent bioinformatic filtering employing Gene 
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Ontology and pathway data (Figures 5 and 6). From 100 SNO-proteins identified in 
wild-type synaptosomes, the majority was linked to various metabolic pathways 
including: oxidative phosphorylation and energy derivation by oxidation of organic 
compounds (6 and 24 proteins respectively) and synaptic functions, involving 
synaptic transmission (18 proteins; Figure 5 and Supplemental Table S4A). The 
participation of synaptic SNO-proteins in numerous protein classes has been 
previously described (8, 82). Interestingly, we found for the first time that 5 proteins 
linked to synaptic transmission in wild-type synaptosomes (GO:0007268; P=1.22E-4, 
Supplemental Table S4A) can also be S-nitrosylated (Camk2b, Cplxn1, Kclna2, 
Nptn and Synj1). S-nitrosylation of both protein kinases and phosphatases influences 
a wide range of signal transduction pathways mediated by 
phosphorylation/dephosphorylation (reviewed in (81)). In this view, regulation of 
Camk2b, Calcium/calmodulin-dependent protein kinase type II beta chain might be 
important for regulation of synaptic transmission. 
To link the changes in S-nitrosylation with advancement of Alzheimer’s 
disease we used a 14 month old transgenic hAPPV717I (hAPP) mouse strain with 
high neuronal expression of human transgene which recapitulates important 
pathological and clinical hallmarks of AD, correlated with high burden and 
accelerated accumulation of A40/42. In order to identify a possibly full spectrum of 
S-nitrosylation changes we narrowed our investigations to the advanced stage at 
which mice start to develop A pathology with neuritic plaques (56, 100).  
AD patients’ brains display elevated level of nitric oxide synthases (70, 71). 
Moreover, it was found that the iNOS reactivity, expression and calcium-independent 
enzymatic activity was increased in APP transgenic (Tg2576 APP) mice and related 
to cortical neurons and microglial cells (101). Deletion of iNOS in these mice 
worsened spatial memory, learning, and tau pathology, suggestive for 
neuroprotective effect of NO (102). Increased levels of iNOS were also detected in 
cortical neurons stimulated with A peptide (103), and confirmed in functional 
experiments demonstrating that A stimulated induction of long-term potentiation was 
inhibited in iNOS knock-out mice (104). Furthermore, treatment with resveratrol 
protected rats from A-induced neurotoxicity by suppressing iNOS production (105). 
Interestingly, in another model of AD (double transgenic APP-PS1 mice) deletion of 
iNOS gene alleviated AD-related pathology including increased A levels, plaque 
21 
 
formation, gliosis and premature mortality (103). We confirmed that level of iNOS 
expression was higher in hAPP synaptosomes as compared to aged-matched 
controls. Changes in the expression of iNOS and nNOS (Figure 1) indicate 
aberrations in the nitric oxide production which may result in subsequent changes of 
protein S-nitrosylation, observed in hAPP synaptosomes (Figure 2). Gow et al. (106) 
demonstrated that increased expression of various nitric oxide synthases leads to 
changes in the level of protein S-nitrosylation in multiple cell types and tissues. 
The key factors determining S-nitrosylation sites in proteins are: (i) spatial 
proximity (i.e. complexing with nNOS regulates the S-nitrosylation of NMDARs and 
PSD-95), (ii) presence of signature SNO motifs adjacent to target Cys residue and (iii) 
local hydrophobicity (i.e. closeness to the membrane) (8, 107). Therefore, in parallel 
to functional clustering analyses we linked the differentially S-nitrosylated proteins 
from hAPP synaptosomes using network approaches. Interestingly, the majority of 
SNO-proteins (95%; 36/38 of all) could be linked to APP via one bridging partner 
resulting in a small network with 59 nodes, when stringent GO BP filtering criteria 
were applied to multiple interaction data (Figure 6). Both functional clustering and 
network approaches revealed that axon guidance term was one of the most enriched 
functional features shared by differentially S-nitrosylated proteins in hAPP 
synaptosomes. Axon guidance term was shared by 6 SNO-proteins of the interaction 
network (Figure 6C), including 5 proteins previously described in literature as 
possible targets of endo/exogenous S-nitrosylation and one novel, GTPase KRas 
precursor (Table 1). The second enriched functional term, “participation in 
cytoplasmic vesicle” (GO:004443) was allotted to 6 SNO-proteins, one of which is a 
novel S-nitrosylation target, Neurocalcin-delta (Ncald/NCALD). S-nitrosylation of this 
target has been exclusively confirmed in the hAPP brain, by Western blotting 
experiments with specific antibodies (Figure 7). Involvement of APP in axonal 
guidance and vesicle trafficking was previously described (Figure 6C; (73, 108-112)). 
Recent in silico analysis of differentially expressed genes in sporadic early onset AD 
revealed an alteration in biological pathways related to intracellular signaling 
including axon guidance among the others (113). Moreover, defects in axon 
guidance were linked to early stage progression of another neurodegenerative 
disorder, Parkinson’s disease (114).  
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The synaptic cytoskeleton is particularly important for synaptic plasticity and 
plays a role in rapid activity-dependent changes of synapse volume or shape. 
Disruptions in the synaptic cytoskeleton affect the stability and maturation of 
synapses and subsequently disturb neuronal communication (115-117). Actin 
cytoskeletal pathology may be an early cause of transport defects in AD (118). One 
of the identified, differentially S-nitrosylated proteins participating in axonal guidance 
is β-actin (Actb). Actin microfilaments supported by actin-associated proteins, are the 
dominant cytoskeletal elements structuring synapses. Local β-actin synthesis in 
developing axons plays an important role in growth cone steering (119). 
S-nitrosylation of β-actin, which increases formation of short actin filaments lead to 
alterations in the cytoskeletal network and inhibited dopamine release (120).  
Another identified SNO-protein, actin severing protein; cofilin (Cfln) affects 
APP transport, synaptic stability and activity (121). siRNA knockdown of cofilin 
abolished both A and RanBP9-induced apoptosis (122). In hippocampal neurons, 
fibrillar A was able to alter the PAK1/LIMK1/cofilin axis and thereby actin 
organization (123).  
Rac1, a small Rho GTPase functions as a positive regulator of neurite 
outgrowth downstream of growth-promoting axon guidance cues. It regulates 
dendritic spines and excitatory synapses, but little is known about its regulation in 
synapses (124). Rac1 is related to increased alterations in the actin cytoskeleton 
induced by fibrillar Aβ (125). It has been hypothesized that Rac1 activation 
exacerbates AD by shifting actin into a polymerized conformation, a phenomenon 
observed in various neurodegenerative disorders (125). Previous studies have also 
shown that the reduction of ROS generation leads to an inhibition of the Rac1 
activation (126).  
An important group of proteins engaged in the axon guidance are those 
connected to the endo/exocytosis processes. AP-2 is the major adaptor protein 
important for sorting of synaptic vesicle proteins during recycling (127). In neurons, 
AP-2-dependent trafficking of NMDA and AMPA receptors is an essential 
determinant of synaptic strength and plasticity (128, 129). S-nitrosylation of AMPA 
receptors resulted in increased endocytosis by binding AP-2 protein (130). 
Levels of Neurocalcin, a calcium binding protein identified to be S- nitrosylated 
for the first time are reduced in AD brain, suggestive for biochemical deficits related 
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to the synaptic degeneration (131). Taken together, the identified changes of S-
nitrosylation of proteins linked to axon guidance and related to endo/exocytosis 
processes underlie an important role of this modification in the regulation of synapses 
in the AD brain. 
Another significantly enriched category of the differentially S-nitrosylated 
proteins identified in hAPP synaptosomes constituted of those involved in energy 
metabolism and oxidative phosphorylation (Figure 6A, B and Supplemental Table 
S5). Modulation of protein function through PTM is probably an important feature of 
energy production at the synapses. Although the brain represents only 2% of the 
body weight, it uses approximately 20% of the total body basal oxygen consumption 
(132). Previous proteomic analyzes reported significant decrease in level of glycolytic 
enzymes in the AD brain and increase in the oxidation of proteins involved in the 
glycolysis and TCA cycle (37, 41).  
In the current study, we showed changes in the S-nitrosylation of 7 proteins 
involved in energy metabolism (Supplemental Table S5A). We, for example, 
identified aberrant S-nitrosylation of GAPDH a key enzyme in glycolysis process 
which catalyzes NAD-mediated oxidative phosphorylation of glyceraldehyde 
phosphate to 1,3-diphosphoglycerate. However, apart from its’ classical role in 
glycolysis, GAPDH takes part in highly diverse, non-glycolytic functions. For example, 
S-nitrosylation of GAPDH enhances binding to SIAH1 protein, an E3 ubiquitin ligase, 
and the complex is translocated to nucleus where it activates apoptosis. In the 
nucleus SNO-GAPDH not only mediates apoptosis but also serves as a 
trans-nitrosylase of other nuclear proteins, including SIRT1, HDAC2 or DNAPK (19). 
SNO-GAPDH dependent molecular pathway leading to neuronal apoptosis may 
contribute to Alzheimer’s disease pathogenesis (76). 
A recent study demonstrated that both GAPDH and gamma enolase were 
oxidatively modified in post mortem AD patients brains (76, 133). Oxidative 
modifications of these enzymes led to inhibition of glycolytic pathways. This is 
consistent with the altered glucose tolerance and metabolic changes confirmed in 
PET analyses of AD patients (134). The impact of S-nitrosylation on the function of 
those proteins is unclear. Aberrant S-nitrosylation of a large number of glycolytic 
enzymes suggests that synapses may be sensitive to glycolytic perturbation, which in 
turn exacerbates Aβ toxicity. 
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We also found a large group of mitochondrial proteins with altered 
S-nitrosylation. There is mounting evidence that mitochondrial dysfunction 
accompanies AD progression and development (135). Mitochondrial dysfunctions are 
consequences of aberrant redox reactions triggered by high level of NO. 
Disturbances in the activity of Complexes I and IV caused by S-nitrosylation have 
been reported in the AD brain (reviewed in (136)). Additionally, a decrease in the 
activity of F1 ATPAse caused by S-nitrosylation was reported in cardiomyocytes (54). 
We found that S-nitrosylated Ndufv1/NDUFV1 and Uqcrc1/UQCRC1, mitochondrial 
complex I and III proteins were either uniquely present (Ndufv1) or more nitrosylated 
(Uqcrc1/UQCRC1) in APP brains (Supplemental Table S2). 
Summarizing, these results suggest that altered S-nitrosylation of proteins 
involved in energy metabolism might be one of the main events associated with AD, 
leading to reduced activity of metabolic pathways and therefore decreased ATP 
production, confirming the previous observations. 
Cellular “S-nitrosome” homeostasis is regulated by enzymatic and non-
enzymatic nitrosylation, denitrosylation and the overall redox milieu. The current work 
was based on systematic profiling of S-nitrosylations in brain synaptosomes from 
wild-type and AD mice. We have identified several endogenous SNO-sites 
exclusively in the hAPP brain, which further contributes to our understanding of 
synaptic complexity and its alterations in AD. It also implicates S-nitrosylation in the 
interplay of various PTM controlling the signaling cascades in the brain, in normal 
and neurodegenerative conditions, and identifies novel putative drug targets for 
therapeutic interventions. Further research is necessary to decipher the precise role 
of S-nitrosylation in the function of identified synaptic proteins. 
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Legends: 
Figure 1. Western blot analysis of iNOS and nNOS expression in the brain. The 
expression of both enzymes was analyzed in wild-type (FVB, lane 1) and transgenic 
APP (hAPP, lane 2) total mouse brain cortex lysates. Gapdh protein expression was 
used for normalization. kDa- molecular weight in kilo-Daltons.  
Figure 2. Western blot analysis of S-nitrosylation pattern in the FVB and hAPP 
brains. S-nitrosylation sites were selectively labeled with S-S-biotin (BST). 
Visualization of biotinylated proteins was achieved with anti-biotin antibodies. 
Controls were prepared without selective ascorbate (Asc) reduction of SNO bonds 
(lane 1 and 2). Pattern of S-nitrosylation of synaptosomal proteins from FVB and 
hAPP mouse brain is presented in lanes 3 and 4, respectively. 
Figure 3. Scheme of S-nitrosylation enrichment methodology. Mouse brain 
synaptosomes were isolated and S-nitrosylated proteins enriched using Biotin Switch 
Technique. After trypsin digestion and enrichment on Neutravidin agarose, the SNO-
peptides were analyzed by LC-MS/MS using in house developed MSparky software. 
Figure 4. Venn diagram comparisons of the numbers of S-nitrosylated proteins (A) 
and S-nitrosylation sites (B) identified in synaptosomes isolated from FVB and hAPP 
mouse brains. C. Scheme of S-nitrosylation pattern in S-nitroso-wt and S-nitroso-all 
sets showing differential and sequential S-nitrosylation, respectively. The details on 
number of SNO-Cys and SNO-sites identified in this study with respective 
UniProtKB/Swiss-Prot IDs and NCBI Gene Symbols are given in Supplemental 
Figure S5. 
Figure 5. ClueGO analysis of S-nitrosylated proteins from FVB mouse brain 
synaptosomes. GO biological process (GO BP, upper panel) and KEGG pathway 
(KEGG, lower panel) terms specific for S-nitrosylated proteins from the FVB brain 
synaptosomes (**-P≤0.01, *-P≤0.05). The number of corresponding genes 
associated with a specific term is indicated. The percentage of genes associated with 
a specific term is listed on the bars. Ungrouped terms are shown in yellow.  
Figure 6. (A) ClueGO analysis of S-nitrosylated proteins from hAPP mouse brain 
synaptosomes. GO biological process/KEGG pathway terms specific for S-
nitrosylated proteins from the FVB brain (*-P≤0.05; **-P≤0.01). The number of 
corresponding genes associated with a specific term is indicated as percentage 
(numbers on bars) and on x axis. Ungrouped terms are indicated in yellow. (B) The 
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networks of functionally grouped terms with nodes linked based on their kappa score 
(≥0.3). Terms not grouped are shown in yellow. (C) Interaction network linking human 
orthologs of differentially SNO-proteins detected in hAPP synaptosomes and Amyloid 
 precursor protein (APP). The network was sorted according to GO BP criteria. The 
size of nodes, representing SNO-proteins (in orange) is proportional to the number of 
SNO-sites, measured in LC-MS/MS experiments. The nodes sharing two most 
enriched functional terms, axon guidance and cytoplasmic vesicle part are presented 
as constituents of network modules (represented by dotted spheres). 
Figure 7. Western blot analysis of S-nitrosylated proteins from hAPP brain 
synaptosomes. (A) Synaptosomal SNO-proteins enriched using BST were detected 
with specific antibodies. Differential SNO set: Ncam1 - Neural cell adhesion 
molecule, Ap2a1 - AP-2 complex subunit alpha-1, Gfap - Glial fibrillary acidic protein, 
Eno2 - Gamma enolase, Syt1, Syt2 - Synaptotagmin-1 and 2, Gapdh - 
glyceraldehyde-3-phosphate dehydrogenase, Ncald - neurocalcin-delta,  Prxd3 - 
peroxiredoxin 3, Rac1- Ras-related C3 botulinum toxin substrate 1 precursor.  Non-
differential SNO set: Syp- synaptophysin, Prxd6 - peroxiredoxin 6. Lane 1 - total FVB 
mouse brain lysate, lane 2 - total hAPP brain lysate, lane 3 - soluble fraction (FVB), 
lane 4 - soluble fraction (hAPP); lane 5 - proteins enriched on neutravidin resin using 
BST (FVB), lane 6 - neutravidin resin after elution (FVB), lane 7 - proteins enriched 
on neutravidin resin using BST (hAPP), lane 8 - neutravidin resin after elution 
(hAPP). kDa- molecular weight in kilo-Daltons. (B) Densitometric quantitation of lanes 
5 (Neutr_FVB) and 7 (Neutr_hAPP); n=3 experiments, P values from t-test. **-
P≤0.01; ***-P≤0.001. 
Table 1. List of identified, differentially SNO-proteins and corresponding peptides in 
the synaptosomes of hAPP transgenic mice. Legend of the Table 1 is included on the 
bottom. 
 
 
 
 
 
 
 
Table 1: List of identified, differentially S-nitrosylated proteins and corresponding 
peptides in the synaptosomes from hAPP transgenic mice. 
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Name  ID 
Gene 
Symbol 
Peptide sequence 
SNO-
pept 
SNO-
Cys 
Cys Ref 
Acylphosphatase-2  P56375# Acyp2 SVDYEVFGTVQGVC30FR #    + 1 1 (107) 
Glial fibrillary acidic 
protein  
P03995* Gfap QLQALTC291DLESLR    + 1 1 (92, 137) 
Neurocalcin-delta  Q91X97 Ncald LLQC185DPSSAGQF    + 1 2   
40S ribosomal protein 
S11  
P62281# Rps11 C60PFTGNVSIR #    
+ 
1 3 (107) 
Heat shock cognate 
71 kDa protein  
P63017#* Hspa8 
GPAVGIDLGTTYSC17VGVFQ
HGK    
+ 1 4 
(53, 92, 
107, 138-
140) 
Ubiquitin-conjugating 
enzyme E2 D3  
P61079# Ube2d3 IYHPNINSNGSIC85LDILR #    + 1 4   
Cofilin-1  P18760# Cfl1 AVLFC39LSEDKK #    + 1 4 (107, 141) 
Thioredoxin-
dependent peroxide 
reductase, 
mitochondrial 
P20108# Prdx3 
AFQFVETHGEVC230PANWTP
ESPTIKPSPTASK #    
+ 1 4 (107) 
MAGUK p55 
subfamily member 2  
Q9WV34# Mpp2 
DLELTPTSGTLC310GSLSGK 
#    
+ 1 5 (50, 142) 
GTPase KRas  P32883 Kras TGEGFLC80VFAINNTK    + 1 5   
Methylglutaconyl-CoA 
hydratase, 
mitochondrial 
Q9JLZ3# Auh SEVPGIFC113AGADLK #    + 1 5 (107) 
Synaptotagmin-1  P46096* Syt1 LGDIC277FSLR    + 1 6 (139) 
Acetyl-CoA 
acetyltransferase, 
mitochondrial 
Q8QZT1#* Acat1 
QATLGAGLPISTPC116TTVNK 
*#   
+ 1 6 (107, 138) 
Fructose-
bisphosphate aldolase 
C  
P05063# Aldoc C290PLPRPWALTFSYGR #    + 1 7 
(92, 107, 
139) 
Synaptotagmin-2  P46097# Syt2 LTVC293ILEAK #    + 1 9 (142) 
P2X purinoceptor 6  O54803 P2rx6 LC347DLLLLYVDR    + 1 13   
Choline transporter-
like protein 2  
Q8BY89 Slc44a2 VVDDTAC401PLLR    + 1 26   
Neuronal growth 
regulator 1 
Q80Z24 Negr1 
DYSLQIQNVDVTDDGPYT 
C112SVQTQHTPR    
+ 1 12   
LanC-like protein 2  Q9JJK2 Lancl2 TIVC187QESELPDELLYGR    + 1 13   
Ly-6/neurotoxin-like 
protein 1  
Q9WVC2 Lynx1 KSC64VPSC68FETVYDGYSK    + 1v2 10   
Metallothionein-1  P02802#* Mt1 SC33C34SC36C37PVGC41SK *#    + 
1v2v3
v4v5 
20 (107) 
Creatine kinase B-
type  
Q04447#* Ckb 
FC254TGLTQIETLFK    + 
2 5 
(53, 139, 
141) LGYILTC283PSNLGTGLR *#    + 
Vacuolar ATP 
synthase subunit B, 
brain isoform  
P62814# Atp6v1b2 
KTSC112EFTGDILR    + 
2 6 (50, 142) 
LALTTAEFLAYQC289EK   + 
Actin, cytoplasmic 1  P60710#* Actb 
LC217YVALDFEQEMATAASS
SSLEK #    
+ 
2 6 
(53, 92, 
107, 138, 
139, 141, 
143) C285DVDIR #    + 
Myelin-
oligodendrocyte 
glycoprotein  
Q61885 Mog 
ALVGDEAELPC52R    + 
2 7   
FSDEGGYTC126FFR    + 
Sodium/potassium-
transporting ATPase 
subunit beta-2  
P14231 Atp1b2 
SC10GQVVEEWKEFVWNPR + 
2 7   NDVC129RPGR + 
ALANSLAC338QGK *# + 
Neural cell adhesion 
molecule 1, 180 kDa 
isoform precursor  
P13595* Ncam1 
FFLC41QVAGDAK + 
2 14 (139) NAPTPQEFKEGEDAVIVC139D
VVSSLPPTIIWK + 
Elongation factor 2  P58252#* Eef2 
STLTDSLVC41K # + 
2 17 
(107, 138, 
141) ETVSEESNVLC591LSK *# + 
Sarcoplasmic/endopla
smic reticulum 
calcium ATPase 2 
O55143#* Atp2a2 
VGEATETALTC447LVEK *# + 
2 29 (107, 138) 
NYLEQPGKEC998VQPATK # + 
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Fructose-bisphosphate 
aldolase A  
P05064*# Aldoa 
YASIC178QQNGIVPIVEP
EILPDGDHDLKR # 
+ 
2 8 
(92, 107, 
139) 
ALANSLAC339QGK *#    + 
Hexokinase-1  P17710*# Hk1 
QTSLDC669GILITWTK + 
2 23 (107) C942TVSFLLSEDGSGK 
#     
+ 
Glyceraldehyde-3-
phosphate dehydrogenase  
P16858#* Gapdh 
IVSNSC150TTNC154LAPL
AK *# 
+ 
2v3 5 
(92, 107, 
138, 
143, 
144) 
VPTPNVSVVDLTC245R 
*# 
+ 
ADP/ATP translocase 1 P48962*# Slc25a4 
EFNGLGDC160LTK *# + 
3 4 (107) 
YFAGNLASGGAAGATS
LC129FVYPLDFAR # 
+ 
GADIMYTGTLDC257WR 
*# 
+ 
Triosephosphate isomerase  P17751#* Tpi1 
IAVAAQNC117YK *# + 
3 6 
(92, 107, 
138, 
143, 
144) 
VSHALAEGLGVIAC177I
GEK # 
+ 
IIYGGSVTGATC268K *# + 
Ras-related C3 botulinum 
toxin substrate 1 
P63001# Rac1 
HHC105PNTPIILVGTK  # + 
3 7 (107) YLEC157SALTQR # + 
AVLC178PPPVK # + 
AP-2 complex subunit 
alpha-1 
P17426# Ap2a1 
ALQVGC941LLR # + 
3 19 (107) LVEC283LETVLNK + 
HLC970ELLAQQF + 
2',3'-cyclic nucleotide 3' 
phosphodiesterase 
P16330# Cnp 
LDCAQLKEKPELQFPF
LQDEDTVATLHEC49K 
+ 
4 7 (145) 
LDEDLAGYC111R # + 
LDC157AQLK + 
AHVTLGC334AADVQPV
QTGLDLLDILQQVK 
+ 
NADH dehydrogenase 
[ubiquinone] flavoprotein 1, 
mitochondrial 
Q91YT0*# Ndufv1 
NAC187GSDYDFDVFVV
R # 
+ 3v4 12 (107) 
GAGAYIC206GEETALIE
SIEGK # 
LKPPFPADVGVFGC238
PTTVANVETVAVSPTIC
255R # 
Legend: Name- UniProtKB/Swiss-Prot name, ID- UniProtKB/Swiss-Prot database unique 
identifier; Gene Symbol- NCBI official Gene Symbol, Mus Musculus; Peptide sequence- 
sequence of the Cys containing peptide identified in our MS/MS experiments; SNO-peptide- 
SNO-peptides detected in MS/MS measurements; Cys- number of Cysteines in a given 
protein sequence; #- literature described endogenous S-nitrosylation of Cys from a given 
peptide sequence; *- literature described exogenous S-nitrosylation of Cys from a given 
peptide sequence. Ref- Literature citation (see references). All Cys in the sequence are bold 
marked. Differentially SNO-Cysteines are marked in red. The aminoacid position of Cys-
SNO is given in subscript. In cases where SNO modification could not be unambiguously 
assigned (i.e. 2v3), the potentially SNO-Cys (in bold red) are underlined. Ref- cited 
literature.  
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